Literature DB >> 9694153

Mapping the in vivo distribution of herpes simplex virions.

D Schellingerhout1, A Bogdanov, E Marecos, M Spear, X Breakefield, R Weissleder.   

Abstract

We describe a method for labeling enveloped viral particles with a radiotracer, indium-111, allowing labeled viruses to be traced in vivo by nuclear imaging. After initial optimization experiments, a labeling efficiency of 83% (incorporation yield) was achieved for herpes simplex virus (HSV), resulting in a specific activity of 30 microCi/10(9) PFU. The labeling procedure did not significantly reduce the infectivity of the labeled virus and the virus did not release any significant amounts of the radionuclide within 12 hr after labeling. Sequential imaging of animals after intravenous administration of the labeled virus showed fast accumulation in the liver and redistribution from the blood pool (immediately after injection) to liver and spleen (12-24 hr after injection). At 12 hr after injection 7% of the virus-associated (111)In had been eliminated from the body and the remaining organ distribution of the virus was as follows: spleen 2.87 +/- 0.54% ID/g; liver, 2.60 +/- 0.51% ID/g; kidney, 0.98 +/- 0.31% ID/g; lung, 0.57 +/- 0.10% ID/g; [corrected] and lower amounts in other organs. Our results indicate that the described method allows qualitative and quantitative assessment of viral biodistribution in vivo by nuclear imaging.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694153     DOI: 10.1089/hum.1998.9.11-1543

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  12 in total

1.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

Review 2.  The status of gene therapy for brain tumors.

Authors:  Giulia Fulci; E Antonio Chiocca
Journal:  Expert Opin Biol Ther       Date:  2007-02       Impact factor: 4.388

Review 3.  Gene therapy imaging in patients for oncological applications.

Authors:  Iván Peñuelas; Uwe Haberkorn; Shahriar Yaghoubi; Sanjiv S Gambhir
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

4.  The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent.

Authors:  N J DePolo; C E Harkleroad; M Bodner; A T Watt; C G Anderson; J S Greengard; K K Murthy; T W Dubensky; D J Jolly
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

5.  Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.

Authors:  Hideo Nakamura; Hideki Kasuya; John T Mullen; Sam S Yoon; Timothy M Pawlik; Soundararajalu Chandrasekhar; James M Donahue; E Antonio Chiocca; Richard Y Chung; Kenneth K Tanabe
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

6.  Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity.

Authors:  Xinping Fu; Armando Rivera; Lihua Tao; Xiaoliu Zhang
Journal:  Mol Ther       Date:  2012-06-12       Impact factor: 11.454

7.  VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy.

Authors:  F K Eshun; M A Currier; R A Gillespie; J L Fitzpatrick; W H Baird; T P Cripe
Journal:  Gene Ther       Date:  2010-05-27       Impact factor: 5.250

8.  Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.

Authors:  Timothy P Cripe; Chun-Yu Chen; Nicholas L Denton; Kellie B Haworth; Brian Hutzen; Jennifer L Leddon; Keri A Streby; Pin-Yi Wang; James M Markert; Alicia M Waters; George Yancey Gillespie; Elizabeth A Beierle; Gregory K Friedman
Journal:  Mol Ther Oncolytics       Date:  2015-09-16       Impact factor: 7.200

9.  Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.

Authors:  Patrizia Nanni; Valentina Gatta; Laura Menotti; Carla De Giovanni; Marianna Ianzano; Arianna Palladini; Valentina Grosso; Massimiliano Dall'ora; Stefania Croci; Giordano Nicoletti; Lorena Landuzzi; Manuela Iezzi; Gabriella Campadelli-Fiume; Pier-Luigi Lollini
Journal:  PLoS Pathog       Date:  2013-01-31       Impact factor: 6.823

Review 10.  Postexit surface engineering of retroviral/lentiviral vectors.

Authors:  Christoph Metzner; Feliks Kochan; John A Dangerfield
Journal:  Biomed Res Int       Date:  2013-04-17       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.